Ocugen Yönetim

Yönetim kriter kontrolleri 2/4

Ocugen CEO'su Shankar Musunuri, Sep2013 tarihinde atandı, in görev süresi 11.17 yıldır. in toplam yıllık tazminatı $ 4.54M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.7% maaş ve 83.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.64% ine doğrudan sahiptir ve bu hisseler € 1.65M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 4.8 yıldır.

Anahtar bilgiler

Shankar Musunuri

İcra Kurulu Başkanı

US$4.5m

Toplam tazminat

CEO maaş yüzdesi	16.7%
CEO görev süresi	11.2yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Shankar Musunuri'un ücretlendirmesi Ocugen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$51m
Jun 30 2024	n/a	n/a	-US$50m
Mar 31 2024	n/a	n/a	-US$58m
Dec 31 2023	US$5m	US$758k	-US$63m
Sep 30 2023	n/a	n/a	-US$79m
Jun 30 2023	n/a	n/a	-US$90m
Mar 31 2023	n/a	n/a	-US$86m
Dec 31 2022	US$8m	US$715k	-US$87m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$69m
Dec 31 2021	US$8m	US$541k	-US$58m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$2m	US$500k	-US$34m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$572k	US$420k	-US$20m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$431k	US$420k	-US$18m

Tazminat ve Piyasa: Shankar 'nin toplam tazminatı ($USD 4.54M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 787.21K ).

Tazminat ve Kazançlar: Shankar 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Shankar Musunuri (60 yo)

11.2yrs

Görev süresi

US$4,535,231

Tazminat

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. since September 2013 and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Pr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shankar Musunuri	Co-Founder	11.2yrs	US$4.54m	0.64% € 1.7m
Uday Kompella	Co-founder & Independent Director	11.2yrs	US$102.13k	0.24% € 620.3k
Arun Upadhyay	Chief Scientific Officer and Head of Research & Development	2.2yrs	US$1.38m	0.037% € 96.0k
Ramesh Ramachandran	Principal Financial Officer & Principal Accounting Officer	less than a year	Veri yok	0.00062% € 1.6k
John Kouch	General Counsel	no data	Veri yok	Veri yok
Tiffany Hamilton	AVP & Head of Corporate Communications	no data	Veri yok	Veri yok
Kristen Craft	Head of People & Culture	less than a year	Veri yok	Veri yok
Michael Shine	Senior Vice President of Commercial	3.4yrs	Veri yok	Veri yok
Jyothy Pillai	VP & Head of Regulatory & Quality	1.8yrs	Veri yok	Veri yok
Huma Qamar	Chief Medical Officer	less than a year	Veri yok	0.00056% € 1.4k
Durgaprasad Annavajjula	VP, Head of Program Management & Chief of Staff	less than a year	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 2H51 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shankar Musunuri	Co-Founder	5.2yrs	US$4.54m	0.64% € 1.7m
Uday Kompella	Co-founder & Independent Director	5.2yrs	US$102.13k	0.24% € 620.3k
Prabhavathi Fernandes	Lead Independent Director	4.6yrs	US$124.63k	0% € 0
Marna Whittington	Independent Director	2.7yrs	US$103.32k	0.00034% € 871.4
Carl Regillo	Member of Retina Scientific Advisory Board	5yrs	Veri yok	Veri yok
David Boyer	Member of Retina Scientific Advisory Board	no data	Veri yok	Veri yok
Bruce Forrest	Vaccine Scientific Advisory Board Member	3.9yrs	Veri yok	Veri yok
Junge Zhang	Independent Director	5.2yrs	US$87.13k	0.40% € 1.0m
Geeta Lalwani	Member of Retina Scientific Advisory Board	no data	Veri yok	Veri yok
Kirsten Castillo	Independent Director	4.6yrs	US$110.82k	0.017% € 44.0k
Satishchandran Chandrasekhar	Vaccine Scientific Advisory Board Member	3.9yrs	Veri yok	Veri yok
Mark Pennesi	Member of Retina Scientific Advisory Board	5yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2H51 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Ocugen Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Insufficient new directors

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Recent updates

Ocugen, Inc. Announces Compelling Preliminary Data for OCU410--Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces Executive Changes

New major risk - Revenue and earnings growth

Ocugen, Inc. announced that it has received $30 million in funding

Ocugen, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

New minor risk - Shareholder dilution

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy

Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication

Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc

Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Insufficient new directors

Forecast to breakeven in 2026

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Independent Director recently bought €92k worth of stock

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

No longer forecast to breakeven

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen, Inc. Announces Board Changes

No longer forecast to breakeven

Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152)

Forecast breakeven date pushed back to 2023

Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022

High number of new and inexperienced directors

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer